Teva Settles With San Francisco But New York Could Be Set To Prize Open Old Wounds

Shadow Of The Opioid Crisis Looms Large Over Israeli Generics Firm

 
• By Chloe Kent
  
Generate a summary of this article
Listen to this article
Beta

Teva has settled the final outstanding advanced US state-level opioid-related case against the firm, but recent allegations from the New York attorney general could see the firm back in court sooner rather than later.

Lady Justice statue
Teva has settled multiple opioid cases raised against the firm • Source: Shutterstock

The final advanced state-level opioid-related claim outstanding against Israeli generics firm Teva has now been settled, with the firm agreeing to pay the county and city of San Francisco $24.8m over the next 13 years to resolve its share of the litigation. It will also supply the state with $20m of its generic version of opioid-overdose nasal spray Narcan (naloxone hydrochloride) over the next decade.

While the firm has expressed that it hopes to make a nationwide settlement by the end of the year, the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By Nabil

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By Akriti Seth

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By David Wallace

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin